Harry R Büller1, Claudette Bethune, Sanjay Bhanot, David Gailani, Brett P Monia, Gary E Raskob, Annelise Segers, Peter Verhamme, Jeffrey I Weitz. 1. From the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.), and International Trial Expertise Advisory and Services (ITREAS) (A.S.) - both in Amsterdam; Isis Pharmaceuticals, Carlsbad, CA (C.B., S.B., B.P.M.); Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville (D.G.); University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); and the Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, ON, Canada (J.I.W.).
Abstract
BACKGROUND: Experimental data indicate that reducing factor XI levels attenuates thrombosis without causing bleeding, but the role of factor XI in the prevention of postoperative venous thrombosis in humans is unknown. FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels. We compared the efficacy and safety of FXI-ASO with those of enoxaparin in patients undergoing total knee arthroplasty. METHODS: In this open-label, parallel-group study, we randomly assigned 300 patients who were undergoing elective primary unilateral total knee arthroplasty to receive one of two doses of FXI-ASO (200 mg or 300 mg) or 40 mg of enoxaparin once daily. The primary efficacy outcome was the incidence of venous thromboembolism (assessed by mandatory bilateral venography or report of symptomatic events). The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: Around the time of surgery, the mean (±SE) factor XI levels were 0.38±0.01 units per milliliter in the 200-mg FXI-ASO group, 0.20±0.01 units per milliliter in the 300-mg FXI-ASO group, and 0.93±0.02 units per milliliter in the enoxaparin group. The primary efficacy outcome occurred in 36 of 134 patients (27%) who received the 200-mg dose of FXI-ASO and in 3 of 71 patients (4%) who received the 300-mg dose of FXI-ASO, as compared with 21 of 69 patients (30%) who received enoxaparin. The 200-mg regimen was noninferior, and the 300-mg regimen was superior, to enoxaparin (P<0.001). Bleeding occurred in 3%, 3%, and 8% of the patients in the three study groups, respectively. CONCLUSIONS: This study showed that factor XI contributes to postoperative venous thromboembolism; reducing factor XI levels in patients undergoing elective primary unilateral total knee arthroplasty was an effective method for its prevention and appeared to be safe with respect to the risk of bleeding. (Funded by Isis Pharmaceuticals; FXI-ASO TKA ClinicalTrials.gov number, NCT01713361.).
RCT Entities:
BACKGROUND: Experimental data indicate that reducing factor XI levels attenuates thrombosis without causing bleeding, but the role of factor XI in the prevention of postoperative venous thrombosis in humans is unknown. FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels. We compared the efficacy and safety of FXI-ASO with those of enoxaparin in patients undergoing total knee arthroplasty. METHODS: In this open-label, parallel-group study, we randomly assigned 300 patients who were undergoing elective primary unilateral total knee arthroplasty to receive one of two doses of FXI-ASO (200 mg or 300 mg) or 40 mg of enoxaparin once daily. The primary efficacy outcome was the incidence of venous thromboembolism (assessed by mandatory bilateral venography or report of symptomatic events). The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: Around the time of surgery, the mean (±SE) factor XI levels were 0.38±0.01 units per milliliter in the 200-mg FXI-ASO group, 0.20±0.01 units per milliliter in the 300-mg FXI-ASO group, and 0.93±0.02 units per milliliter in the enoxaparin group. The primary efficacy outcome occurred in 36 of 134 patients (27%) who received the 200-mg dose of FXI-ASO and in 3 of 71 patients (4%) who received the 300-mg dose of FXI-ASO, as compared with 21 of 69 patients (30%) who received enoxaparin. The 200-mg regimen was noninferior, and the 300-mg regimen was superior, to enoxaparin (P<0.001). Bleeding occurred in 3%, 3%, and 8% of the patients in the three study groups, respectively. CONCLUSIONS: This study showed that factor XI contributes to postoperative venous thromboembolism; reducing factor XI levels in patients undergoing elective primary unilateral total knee arthroplasty was an effective method for its prevention and appeared to be safe with respect to the risk of bleeding. (Funded by Isis Pharmaceuticals; FXI-ASO TKA ClinicalTrials.gov number, NCT01713361.).
Authors: Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Husam S Younis; Jeff Crosby; Jung-Im Huh; Hong Soo Lee; Soyub Rime; Brett Monia; Scott P Henry Journal: Blood Date: 2012-01-13 Impact factor: 22.113
Authors: Hong Zhang; Ester C Löwenberg; Jeffrey R Crosby; A Robert MacLeod; Chenguang Zhao; Dacao Gao; Chris Black; Alexey S Revenko; Joost C M Meijers; Erik S Stroes; Marcel Levi; Brett P Monia Journal: Blood Date: 2010-08-31 Impact factor: 22.113
Authors: Peter Verhamme; Sophie Gunn; Elisabeth Sonesson; Kathelijne Peerlinck; Thomas Vanassche; Christophe Vandenbriele; Walter Ageno; Steven Glazer; Martin Prins; Harry Buller; Marco Tangelder Journal: Thromb Haemost Date: 2013-04-25 Impact factor: 5.249
Authors: Jeffrey R Crosby; Ulla Marzec; Alexey S Revenko; Chenguang Zhao; Dacao Gao; Anton Matafonov; David Gailani; A Robert MacLeod; Erik I Tucker; Andras Gruber; Stephen R Hanson; Brett P Monia Journal: Arterioscler Thromb Vasc Biol Date: 2013-04-04 Impact factor: 8.311
Authors: Erik I Tucker; Ulla M Marzec; Tara C White; Sawan Hurst; Sandra Rugonyi; Owen J T McCarty; David Gailani; András Gruber; Stephen R Hanson Journal: Blood Date: 2008-10-22 Impact factor: 22.113
Authors: Felicitas Müller; Nicola J Mutch; Wolfdieter A Schenk; Stephanie A Smith; Lucie Esterl; Henri M Spronk; Stefan Schmidbauer; William A Gahl; James H Morrissey; Thomas Renné Journal: Cell Date: 2009-12-11 Impact factor: 41.582
Authors: Yuichi Kamikubo; G Loredana Mendolicchio; Antonella Zampolli; Patrizia Marchese; Andrea S Rothmeier; Jennifer Nagrampa Orje; Andrew J Gale; Sriram Krishnaswamy; András Gruber; Henrik Østergaard; Lars C Petersen; Wolfram Ruf; Zaverio M Ruggeri Journal: Blood Date: 2017-07-20 Impact factor: 22.113
Authors: Christina U Lorentz; Norah G Verbout; Michael Wallisch; Matthew W Hagen; Joseph J Shatzel; Sven R Olson; Cristina Puy; Monica T Hinds; Owen J T McCarty; David Gailani; András Gruber; Erik I Tucker Journal: Arterioscler Thromb Vasc Biol Date: 2019-04 Impact factor: 8.311
Authors: Yasin Kokoye; Ivan Ivanov; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Shauna Mason; Daniel J Sexton; Thomas Renné; Keith McCrae; Edward P Feener; David Gailani Journal: Thromb Res Date: 2016-02-18 Impact factor: 3.944
Authors: Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik Journal: Blood Date: 2015-08-18 Impact factor: 22.113